1-(4-Methyl-3-morpholin-4-ylsulfonylphenyl)ethanone | 1123297-13-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-(4-Methyl-3-morpholin-4-ylsulfonylphenyl)ethanone
• CAS: 1123297-13-1
• 化学式: C₁₃H₁₇NO₄S
• 分子量: 283.348
• InChiKey: CFRSOHNCJSFUCL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  72.1
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-(4-Methyl-3-morpholin-4-ylsulfonylphenyl)ethanone 在 benzyltrimethylazanium tribroman-2-uide 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 以47%的产率得到2-bromo-1-(4-methyl-3-(morpholinosulfonyl)phenyl)ethan-1-one
  参考文献：
  名称：

  CB2 selective sulfamoyl benzamides: Optimization of the amide functionality

  摘要：

  Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.091
• 作为产物：
  描述：

  N-methoxy-N,4-dimethyl-3-morpholin-4-ylsulfonylbenzamide 、 甲基溴化镁 以 四氢呋喃 、 乙醚 为溶剂， 以92%的产率得到1-(4-Methyl-3-morpholin-4-ylsulfonylphenyl)ethanone
  参考文献：
  名称：

  CB2 selective sulfamoyl benzamides: Optimization of the amide functionality

  摘要：

  Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered. (C) 2008 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2008.11.091

文献信息

• CB2 selective sulfamoyl benzamides: Optimization of the amide functionality
  作者：Allan J. Goodman、Christopher W. Ajello、Karin Worm、Bertrand Le Bourdonnec、Markku A. Savolainen、Heather O’Hare、Joel A. Cassel、Gabriel J. Stabley、Robert N. DeHaven、Christopher J. LaBuda、Michael Koblish、Patrick J. Little、Bernice L. Brogdon、Steven A. Smith、Roland E. Dolle

  DOI：10.1016/j.bmcl.2008.11.091

  日期：2009.1

  Previous research within our laboratories identified sulfamoyl benzamides as novel cannabinoid receptor ligands. Optimization of the amide linkage led to the reverse amide 40. The compound exhibited robust antiallodynic activity in a rodent pain model when administered intraperitoneally. Efficacy after oral administration was observed only when ABT, a cytochrome P450 suicide inhibitor, was coadministered. (C) 2008 Elsevier Ltd. All rights reserved.